In Brief: Gliatech Adcon-L
This article was originally published in The Gray Sheet
Executive SummaryGliatech Adcon-L: Resorbable barrier gel's premarket approval application will receive expedited review by FDA, the firm says. The PMA was accepted for filing in February. Adcon-L is intended to act as "a barrier to post surgical peridural fibrosis and adhesions following lumbar surgery" ("The Gray Sheet" Aug. 26, 1996, In Brief)...
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.